# Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

> **NCT07285213** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 230 (estimated)

## Conditions studied

- Clostridioides Difficile Infection

## Interventions

- **DRUG:** AZD5148
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07285213
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2027-04-20
- **Final completion:** 2028-01-18
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285213, "Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07285213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*